Smaller biotechs see new mechanisms of actions as future of obesity treatments

Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli Lilly (LLY), will mark the